Initial efficacy of anti-lymphocyte activation gene-3 (an combination with nivolumab (nivo) in pts with melanor antiâ€“PD-1/PD-L1 therapy.

Journal of Clinical Oncology

35, 9520-9520

DOI: 10.1200/jco.2017.35.15_suppl.9520

Citation Report

#	Article	IF	Citations
1	Checkpoint inhibitors in melanoma and early phase development in solid tumors: whatâ€™s the future?. Journal of Translational Medicine, 2017, 15, 173.	1.8	36
2	Therapeutic prospects of targeting myeloidâ€derived suppressor cells and immune checkpoints in cancer. Immunology and Cell Biology, 2018, 96, 888-897.	1.0	43
3	Inhibitors of the PD-1 Pathway in Tumor Therapy. Journal of Immunology, 2018, 200, 375-383.	0.4	112
4	The Great Debate at â€œMelanoma Bridgeâ€, Napoli, December 2nd, 2017. Journal of Translational Medicine, 2018, 16, 101.	1.8	3
5	Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology and Oncology, 2018, 11, 39.	6.9	597
6	Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. OncoImmunology, 2018, 7, e1448332.	2.1	54
7	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Annals of Oncology, 2018, 29, 71-83.	0.6	253
8	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. European Journal of Cancer, 2018, 88, 67-76.	1.3	15
9	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 1260-1270.	3.2	289
10	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunology Research, 2018, 6, 1445-1452.	1.6	132
11	Immunotherapy-based combinations: an update. Current Opinion in Oncology, 2018, 30, 345-351.	1.1	25
12	Value-based genomics. Oncotarget, 2018, 9, 15792-15815.	0.8	46
13	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. Annals of Oncology, 2018, 29, 1727-1740.	0.6	20
14	Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma. Clinical Cancer Research, 2018, 24, 5815-5819.	3.2	25
15	Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. Lancet, The, 2018, 392, 97-98.	6.3	5
16	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Current Opinion in Pharmacology, 2018, 41, 114-121.	1.7	97
17	Acquired resistance to cancer immunotherapy. Seminars in Immunopathology, 2019, 41, 31-40.	2.8	34
18	On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. Chemotherapy, 2019, 64, 62-80.	0.8	34

#	Article	IF	Citations
19	LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer. Cancers, 2019, 11, 1213.	1.7	75
20	Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opinion on Investigational Drugs, 2019, 28, 695-708.	1.9	38
21	Immunotherapies for the Treatment of Uveal Melanomaâ€"History and Future. Cancers, 2019, 11, 1048.	1.7	56
22	Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. Advanced Drug Delivery Reviews, 2019, 141, 104-124.	6.6	14
23	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open, 2019, 4, e000472.	2.0	26
24	Monoclonal Antibodies in Dermatooncologyâ€"State of the Art and Future Perspectives. Cancers, 2019, 11, 1420.	1.7	9
25	Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers, 2019, 11, 1756.	1.7	92
26	Novel Targets for the Treatment of Melanoma. Current Oncology Reports, 2019, 21, 97.	1.8	15
27	Novel Immunotherapy Combinations. Current Oncology Reports, 2019, 21, 96.	1.8	12
28	Precision medicine for metastatic colorectal cancer: an evolving era. Expert Review of Gastroenterology and Hepatology, 2019, 13, 919-931.	1.4	34
29	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Seminars in Cancer Biology, 2019, 59, 290-297.	4.3	78
30	Immunobiology of cholangiocarcinoma. JHEP Reports, 2019, 1, 297-311.	2.6	79
31	Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules, 2019, 9, 548.	1.8	43
32	Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3â€"Knockin Mice. Molecular Cancer Therapeutics, 2019, 18, 2051-2062.	1.9	48
33	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. Cancers, 2019, 11, 539.	1.7	45
34	New emerging targets in cancer immunotherapy: the role of LAG3. ESMO Open, 2019, 4, e000482.	2.0	83
35	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2019, 68, 765-772.	2.0	35
36	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 421-432.	1.4	45

#	Article	IF	Citations
37	Immunotherapy in extensive small cell lung cancer. Experimental Hematology and Oncology, 2019, 8, 5.	2.0	32
38	Immune Checkpoints. , 2019, , 19-43.		0
39	Future of Immune Checkpoint Inhibitors. , 2019, , 227-243.		2
40	Rational combination of cancer immunotherapy in melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 433-447.	1.4	7
41	Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell, 2019, 176, 334-347.e12.	13.5	553
42	Advanced stage melanoma therapies: Detailing the present and exploring the future. Critical Reviews in Oncology/Hematology, 2019, 133, 99-111.	2.0	48
43	miR-146a Controls Immune Response in the Melanoma Microenvironment. Cancer Research, 2019, 79, 183-195.	0.4	69
44	The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development. Immunotherapy, 2019, 11, 155-159.	1.0	12
45	Roles, function and relevance of LAG3 in HIV infection. PLoS Pathogens, 2019, 15, e1007429.	2.1	27
46	Revolutionizing treatment of advanced melanoma with immunotherapy. Surgical Oncology, 2019, , 101180.	0.8	12
47	Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Future Oncology, 2019, 15, 349-358.	1.1	34
48	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology, 2019, 75, 435-444.	0.9	97
49	Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. European Journal of Cancer, 2020, 139, 92-98.	1.3	12
50	Antibody and antibody fragments for cancer immunotherapy. Journal of Controlled Release, 2020, 328, 395-406.	4.8	63
51	T cell receptor therapy against melanomaâ€"Immunotherapy for the future?. Scandinavian Journal of Immunology, 2020, 92, e12927.	1.3	8
52	Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. , 2020, 8, e000967.		67
53	Generation of highly activated, antigen-specific tumor-infiltrating CD8 ⁺ T cells induced by a novel T cell-targeted immunotherapy. OncoImmunology, 2020, 9, 1782574.	2.1	2
54	Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy. Medicine in Drug Discovery, 2020, 8, 100073.	2.3	10

#	Article	IF	Citations
55	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Cancers, 2020, 12, 1945.	1.7	49
56	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. Immunotherapy, 2020, 12, 1083-1100.	1.0	27
57	The adverse events associated with combination immunotherapy in cancers: Challenges and chances. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e154-e159.	0.7	11
58	The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment. Cancers, 2020, 12, 3757.	1.7	13
59	Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. Karger Kompass Dermatologie, 2020, 8, 92-101.	0.0	0
60	Alternative Checkpoints as Targets for Immunotherapy. Current Oncology Reports, 2020, 22, 126.	1.8	12
61	Functional and metabolic targeting of natural killer cells to solid tumors. Cellular Oncology (Dordrecht), 2020, 43, 577-600.	2.1	25
62	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 739-753.	1.9	2
63	Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Current Opinion in Rheumatology, 2020, 32, 315-320.	2.0	19
64	Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. International Journal of Oral Science, 2020, 12, 16.	3.6	108
65	LAG3 (CD223) and autoimmunity: Emerging evidence. Journal of Autoimmunity, 2020, 112, 102504.	3.0	28
66	The potentials of immune checkpoints for the treatment of blood malignancies. Critical Reviews in Oncology/Hematology, 2020, 153, 103031.	2.0	4
67	Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy, 2020, 20, 289-304.	1.1	13
68	Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy. Current Oncology Reports, 2020, 22, 38.	1.8	15
69	Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. Cancer Immunology, Immunotherapy, 2020, 69, 1363-1373.	2.0	26
70	Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy. Frontiers in Oncology, 2020, 10, 951.	1.3	35
71	Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antibody Therapeutics, 2020, 3, 18-62.	1.2	54
72	A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. Acta Pharmaceutica Sinica B, 2020, 10, 1047-1060.	5.7	50

#	Article	IF	Citations
73	Anti-PD-1 and Novel Combinations in the Treatment of Melanomaâ€"An Update. Journal of Clinical Medicine, 2020, 9, 223.	1.0	95
74	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. International Journal of Molecular Sciences, 2020, 21, 556.	1.8	21
75	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. International Journal of Cancer, 2020, 147, 1509-1518.	2.3	44
76	<scp>PDâ€Ł1</scp> and <scp>LAG</scp>â€3 expression in advanced cutaneous squamous cell carcinomas. Journal of Cutaneous Pathology, 2020, 47, 882-887.	0.7	14
77	FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. Clinical Cancer Research, 2020, 26, 3333-3344.	3.2	76
78	LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 1367-1377.	2.5	66
79	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 2020, 21, 2367.	1.8	34
80	Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy. Clinical Cancer Research, 2021, 27, 680-688.	3.2	77
81	Advanced Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 111-128.	0.9	5
82	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 2021, 7, 121-134.	1.3	17
83	LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 606-613.	0.6	13
84	Combinatorial Approaches to the Treatment of Advanced Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 145-158.	0.9	5
85	LAG3â€™s Enigmatic Mechanism of Action. Frontiers in Immunology, 2020, 11, 615317.	2.2	92
86	Immune Infiltration Landscape in Clear Cell Renal Cell Carcinoma Implications. Frontiers in Oncology, 2020, 10, 491621.	1.3	15
87	Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. Expert Review of Gastroenterology and Hepatology, 2021, 15, 589-598.	1.4	17
88	How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?. Cancer Journal (Sudbury, Mass), 2021, 27, 134-142.	1.0	1
89	Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. Expert Opinion on Emerging Drugs, 2021, 26, 79-92.	1.0	13
91	Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Clinical and Translational Oncology, 2021, 23, 1885-1904.	1.2	11

#	Article	IF	Citations
92	Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases. Frontiers in Immunology, 2021, 12, 645699.	2.2	18
93	PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Cells, 2021, 10, 1152.	1.8	12
94	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Frontiers in Oncology, 2021, 11, 670726.	1.3	26
95	Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 62-71.	0.6	20
96	Gene of the month: lymphocyte-activation gene 3 (LAG-3). Journal of Clinical Pathology, 2021, 74, 543-547.	1.0	35
97	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nature Reviews Drug Discovery, 2022, 21, 495-508.	21.5	120
98	Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 511-520.	0.6	29
99	LAG3 is not expressed in human and murine neurons and does not modulate Î±â€synucleinopathies. EMBO Molecular Medicine, 2021, 13, e14745.	3.3	44
100	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
101	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research, 2021, 9, 1202-1213.	1.6	71
102	Next-Generation Immunotherapy Approaches in Melanoma. Current Oncology Reports, 2021, 23, 116.	1.8	3
103	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Annals of Oncology, 2021, 32, 1597-1607.	0.6	47
104	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. Expert Review of Anticancer Therapy, 2021, 21, 1211-1228.	1.1	1
105	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. Journal of Cellular Physiology, 2022, 237, 346-372.	2.0	13
106	LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma. Cancers, 2021, 13, 4445.	1.7	26
107	Guiding immunotherapy combinations: Who gets what?. Advanced Drug Delivery Reviews, 2021, 178, 113962.	6.6	8
108	Tumor <scp>LAG</scp>â€3 and <scp>NYâ€ESO</scp>â€1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 619-630.	0.8	8
109	PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. OncoImmunology, 2021, 10, 1943180.	2.1	54

#	Article	IF	Citations
110	Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. Methods in Molecular Biology, 2020, 2055, 23-60.	0.4	12
111	Immunotherapy for Melanoma. Advances in Experimental Medicine and Biology, 2020, 1244, 51-68.	0.8	41
112	Discovery of New Immune Checkpoints: Family Grows Up. Advances in Experimental Medicine and Biology, 2020, 1248, 61-82.	0.8	20
113	Checkpoint inhibitor immunotherapy in kidney cancer. Nature Reviews Urology, 2020, 17, 137-150.	1.9	162
114	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. Journal of Clinical Investigation, 2018, 128, 3209-3218.	3.9	170
115	Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. Journal of Biological Methods, 2019, 6, e114.	1.0	14
116	The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes and Cancer, 2018, 9, 176-189.	0.6	272
117	Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget, 2018, 9, 4375-4384.	0.8	26
118	The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Timeâ€™s a Charm. International Journal of Molecular Sciences, 2021, 22, 75.	1.8	87
119	Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event. Journal of Immunotherapy and Precision Oncology, 2018, 1, 68-77.	0.6	8
120	Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers, 2021, 13, 5295.	1.7	9
121	Targeted Antiâ€Tumor Immunotherapy Using Tumor Infiltrating Cells. Advanced Science, 2021, 8, e2101672.	5.6	36
123	Novel Immunotherapies and Novel Combinations of Immunotherapy. , 2019, , 1-22.		0
124	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24.		0
126	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2020, , 1141-1164.		0
127	Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 2020, 7, 17-26.	0.2	7
128	Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. , 2020, , 1165-1186.		0
129	Immunotherapy for Melanoma. Advances in Experimental Medicine and Biology, 2021, 1342, 81-111.	0.8	7

#	Article	IF	Citations
131	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
132	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine, 2022, 386, 24-34.	13.9	766
133	Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Seminars in Cancer Biology, 2022, 86, 799-815.	4.3	28
134	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. Future Oncology, 2022, , .	1.1	4
135	Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma. Future Oncology, 2022, 18, 1343-1355.	1.1	2
136	New Checkpoint Inhibitors and Immunotherapies for Solid Tumours. Touch Reviews in Oncology & Haematology, 2021, 17, 90.	0.1	0
137	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) Â± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
138	Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications. Chinese Medical Journal, 2022, 135, 1203-1212.	0.9	9
139	A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties. MAbs, 2022, 14, 2044435.	2.6	4
140	Clinical landscape of LAG-3-targeted therapy. Immuno-Oncology Technology, 2022, 14, 100079.	0.2	37
141	Imaging immunity in patients with cancer using positron emission tomography. Npj Precision Oncology, 2022, 6, 24.	2.3	13
142	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. British Journal of Cancer, 2022, 126, 1168-1177.	2.9	9
143	Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers, 2022, 14, 81.	1.7	5
144	Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. Human Vaccines and Immunotherapeutics, 2022, 18, 1-11.	1.4	3
145	LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of TÂcells through dendritic cell activation. Molecular Therapy, 2022, 30, 2800-2816.	3.7	29
146	Double Trouble: Immunotherapy Doublets in Melanomaâ€"Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 745-766.	1.8	6
147	New potential checkpoint inhibitors in cancer therapy. Onkologie (Czech Republic), 2022, 16, 115-117.	0.0	0
148	Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. OncoImmunology, 2022, 11, .	2.1	6

#	Article	IF	Citations
149	Modelling the tumor immune microenvironment for precision immunotherapy. Clinical and Translational Immunology, 2022, 11, .	1.7	16
150	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680.	5.7	18
151	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
152	Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. Cells, 2022, 11, 2351.	1.8	29
153	Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Medicinal Chemistry, 0, , .	1.1	1
154	LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors. International Journal of Molecular Sciences, 2022, 23, 9958.	1.8	21
155	Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3. Journal of Immunology, 2022, 209, 1586-1594.	0.4	4
157	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 13241.	1.8	9
158	Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy. Cancers, 2022, 14, 5046.	1.7	8
159	Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers in Oncology, 0, 12, .	1.3	8
161	Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. Immuno, 2022, 2, 671-691.	0.6	2
162	Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 2023, 15, 1106.	1.7	39
163	Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Antiâ€“Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. Journal of Clinical Oncology, 2023, 41, 2724-2735.	0.8	35
164	Killer to cure: Expression and production costs calculation of tobacco plantâ€made cancerâ€immune checkpoint inhibitors. Plant Biotechnology Journal, 2023, 21, 1254-1269.	4.1	4
165	Tumor Immunophenotypingâ€Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. Advanced Science, 2023, 10, .	5.6	3
166	The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. Current Oncology Reports, 2023, 25, 647-657.	1.8	7
167	Head and neck cancer treatment in the era of molecular medicine. Advances in Cancer Research, 2023, , 205-252.	1.9	2
168	The â€œGreat Debateâ€•at Melanoma Bridge 2022, Naples, December 1stâ€“3rd, 2022. Journal of Translational Medicine, 2023, 21, .	1.8	1

#	Article	IF	Citations
176	Unraveling the Esophageal Cancer Tumor Microenvironment: Insights and Novel Immunotherapeutic Strategies. , 2023, , .		0
183	Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy. Cancer Treatment and Research, 2023, , 49-94.	0.2	0
188	OX40 and CD40 Agonists for the Treatment of Lung Cancer. , 2024, , 181-199.		0